Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T19:56:35.484Z.
Calculation as of: 2026-10-06T19:56:35.484Z.
Quote observation: 2026-10-06T19:55:21.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d443e069440aa0ac5a32f25afa0d38c48efe58a411ec60778b8439bb1c5cf92a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Eledon Pharmaceuticals, Inc.
Market Cap
$187.95M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$190.42M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$182.79M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$181.62M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$179.26M
Price/OCF Ratio
N/A
TTM Avg
28.65
3Y Avg
28.61
5Y Avg
28.61
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | $187.95M | N/A | N/A | N/A | N/A |
| Zentalis Pharmaceuticals, Inc. (ZNTL)vs › | $190.42M | N/A | N/A | N/A | N/A |
| AN2 Therapeutics, Inc. (ANTX)vs › | $183.32M | N/A | N/A | N/A | N/A |
| RxSight, Inc. (RXST)vs › | $192.89M | N/A | N/A | N/A | N/A |
| Compass Therapeutics, Inc. (CMPX)vs › | $182.79M | N/A | N/A | N/A | N/A |
| Canton Strategic Holdings Inc (CNTN)vs › | $181.62M | N/A | N/A | N/A | N/A |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $179.26M | N/A | 28.65 | 28.61 | 28.61 |
| Exagen Inc. (XGN)vs › | $198.84M | N/A | N/A | N/A | N/A |
| Alector, Inc. (ALEC)vs › | $199.29M | N/A | 3.18 | 3.20 | 4.43 |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $199.21M | N/A | 10.01 | 10.01 | 10.01 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
